Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tolerogenic dendritic cell therapy (RASGRP2 peptide-based)
- Development stage
- Preclinical
- Lead developer
- Florey Institute of Neuroscience and Mental Health
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
01
Overview
Tolerogenic dendritic cell therapy (RASGRP2 peptide-based) is an autologous cell therapy under development for the treatment of multiple sclerosis (MS). The therapy utilizes patient-derived dendritic cells that are treated with tolerogenic stimuli and loaded with immunogenic peptides derived from RAS guanyl-releasing protein 2 (RASGRP2), a calcium- and diacylglycerol-regulated nucleotide exchange factor identified as a major autoantigen in HLA-DRB1*15:01 (DR15)-positive MS patients. By presenting these cognate autoantigens in a tolerogenic context, the therapy aims to re-establish antigen-specific immune tolerance, selectively suppressing the pathogenic, autoreactive CD4+ T-cell responses that drive demyelination in MS without causing broad systemic immunosuppression.
- Other names
- tolerogenic dendritic cell-based therapy (RASGRP2 peptide-based)tolerogenic dendritic cell therapy (RASGRP2-based)
Beyond the preview
Go deeper on tolerogenic dendritic cell therapy (RASGRP2 peptide-based).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tolerogenic dendritic cell therapy (RASGRP2 peptide-based).